Product
Pentostatin
Aliases
Nipent
Name
Nipent
INN Name
PENTOSTATIN
FDA Approved
Yes
5 clinical trials
1 organization
20 indications
1 document
Indication
Sickle Cell DiseaseIndication
ThalassemiaIndication
Stem Cell TransplantationIndication
Graft-Versus-Host DiseaseIndication
Hairy Cell LeukemiaIndication
Acute Myeloid LeukemiaIndication
Acute Lymphocytic LeukemiaIndication
Chronic Myelogenous LeukemiaIndication
Chronic Lymphocytic LeukemiaIndication
Myelodysplastic SyndromesIndication
Multiple MyelomaIndication
Non-Hodgkin's LymphomaIndication
Hodgkin's diseaseIndication
Peripheral T-cell LymphomaIndication
Sickle Cell DisorderIndication
HemoglobinopathiesIndication
AnaemiaIndication
Sickle CellIndication
LeukemiaClinical trial
Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia in Individuals With Higher Risk of Transplant FailureStatus: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell LeukemiaStatus: Active (not recruiting), Estimated PCD: 2022-12-15
Clinical trial
Allogeneic Peripheral Blood Stem Cell Transplantation With Minimally Myelosuppressive Regimen of Pentostatin and Low-dose Total-body IrradiationStatus: Completed, Estimated PCD: 2008-12-30
Clinical trial
Pilot Study to Evaluate the Safety and Feasibility of Induction of Mixed Chimerism in Sickle Cell Disease Patients With COH-MC-17: a Non-Myeloablative, Conditioning Regimen and CD4+ T-cell-depleted Haploidentical Hematopoietic TransplantStatus: Active (not recruiting), Estimated PCD: 2024-11-17
Clinical trial
A Phase II Study of Reduced Intensity Allogeneic Bone Marrow Transplant for the Treatment of Myelodysplastic SyndromesStatus: Completed, Estimated PCD: 2014-02-01
Document
DailyMed Label: NipentOrganization
Hospira, Inc.